CN109071462B - 喹唑啉衍生物或其盐和包含其的药物组合物 - Google Patents

喹唑啉衍生物或其盐和包含其的药物组合物 Download PDF

Info

Publication number
CN109071462B
CN109071462B CN201780025602.4A CN201780025602A CN109071462B CN 109071462 B CN109071462 B CN 109071462B CN 201780025602 A CN201780025602 A CN 201780025602A CN 109071462 B CN109071462 B CN 109071462B
Authority
CN
China
Prior art keywords
amino
quinazoline
phenyl
carbonitrile
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780025602.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071462A (zh
Inventor
金暎桓
韩兑东
金东勋
丁恩惠
崔秀份
李义澈
郑元晖
朴鎭辉
朴埈徹
姜镐雄
葛芝莹
朴赞善
金钟均
南受延
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liu Hanyangxing
Original Assignee
Liu Hanyangxing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liu Hanyangxing filed Critical Liu Hanyangxing
Publication of CN109071462A publication Critical patent/CN109071462A/zh
Application granted granted Critical
Publication of CN109071462B publication Critical patent/CN109071462B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780025602.4A 2016-04-29 2017-04-26 喹唑啉衍生物或其盐和包含其的药物组合物 Active CN109071462B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160053033 2016-04-29
KR10-2016-0053033 2016-04-29
PCT/KR2017/004424 WO2017188720A2 (fr) 2016-04-29 2017-04-26 Dérivé de quinazoline ou son sel et composition pharmaceutique le comprenant

Publications (2)

Publication Number Publication Date
CN109071462A CN109071462A (zh) 2018-12-21
CN109071462B true CN109071462B (zh) 2022-02-08

Family

ID=60159881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780025602.4A Active CN109071462B (zh) 2016-04-29 2017-04-26 喹唑啉衍生物或其盐和包含其的药物组合物

Country Status (9)

Country Link
US (1) US10941136B2 (fr)
EP (1) EP3448839B1 (fr)
JP (1) JP6909236B2 (fr)
KR (1) KR102325899B1 (fr)
CN (1) CN109071462B (fr)
AU (1) AU2017256488B2 (fr)
CA (1) CA3019333C (fr)
ES (1) ES2908001T3 (fr)
WO (1) WO2017188720A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6909236B2 (ja) * 2016-04-29 2021-07-28 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ キナゾリン誘導体またはその塩およびそれを含む医薬組成物
US20200165257A1 (en) * 2017-06-22 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer
JP7450541B2 (ja) 2018-01-20 2024-03-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換アミノピリミジン化合物及び使用方法
CN113929674B (zh) * 2021-11-22 2023-09-22 中国药科大学 含1,4-二氢喹唑啉结构的化合物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762565A (zh) * 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN104470923A (zh) * 2012-07-04 2015-03-25 理森制药股份公司 选择性PI3K δ抑制剂
WO2015168079A1 (fr) * 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2775942A1 (fr) * 2009-09-29 2011-04-07 Xcovery Holding Company Llc Inhibiteurs selectifs de la pi3k (delta)
JP6909236B2 (ja) * 2016-04-29 2021-07-28 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ キナゾリン誘導体またはその塩およびそれを含む医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762565A (zh) * 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN104470923A (zh) * 2012-07-04 2015-03-25 理森制药股份公司 选择性PI3K δ抑制剂
WO2015168079A1 (fr) * 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k

Also Published As

Publication number Publication date
WO2017188720A2 (fr) 2017-11-02
EP3448839A4 (fr) 2019-09-11
KR102325899B1 (ko) 2021-11-12
EP3448839B1 (fr) 2022-02-09
US10941136B2 (en) 2021-03-09
CA3019333C (fr) 2024-01-02
ES2908001T3 (es) 2022-04-27
EP3448839A2 (fr) 2019-03-06
JP2019514910A (ja) 2019-06-06
AU2017256488B2 (en) 2020-12-17
KR20170124089A (ko) 2017-11-09
CN109071462A (zh) 2018-12-21
JP6909236B2 (ja) 2021-07-28
US20200325120A1 (en) 2020-10-15
CA3019333A1 (fr) 2017-11-02
WO2017188720A3 (fr) 2018-07-26
AU2017256488A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
CA2926478C (fr) Inhibiteurs de rho kinase
CN109071462B (zh) 喹唑啉衍生物或其盐和包含其的药物组合物
KR20170082637A (ko) 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
TW202122389A (zh) 雜環ｒｉｐ１激酶抑制劑
JP6800158B2 (ja) Ｇｄｆ−８阻害剤
JP2020528907A5 (fr)
EA037103B1 (ru) Производные пиридина, обладающие избирательной ингибирующей активностью в отношении ret киназы
WO2015157556A1 (fr) Traitement de la réaction du greffon contre l'hôte
JP6789941B2 (ja) Ｔｇｆ−ベータ阻害剤としての縮合イミダゾール誘導体
Song et al. Design, synthesis, and biological evaluation of 1, 2, 5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2, 3-dioxygenase 1 inhibitors
JP6609308B2 (ja) キナーゼ阻害剤としての置換マクロサイクル
CN115160309B (zh) Krasg12c突变蛋白杂环类抑制剂的制备及其应用
WO2020038433A1 (fr) Inhibiteur de kinase egfr, son procédé de préparation et son utilisation
IL266126A (en) Pyridone compound as a c – met inhibitor
CN111542522A (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
AU2020404978A1 (en) CD206 modulators their use and methods for preparation
CN116390923A (zh) 杂环类衍生物及其制备方法和用途
WO2014139391A1 (fr) Utilisation de composés de pyridine substituée en tant qu'inhibiteurs de kinases
WO2019218928A1 (fr) Composé d'indoline-1-formamide, son procédé de préparation et son utilisation médicale

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant